BD750

Research use only, not for human use.

BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in mouse and human T cells, respectively).

BD750 is an effective immunosuppressant and a JAK3/STAT5 inhibitor, inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation(IC50 of 1.5 μM and 1.1 μM in mouse and human T cells, respectively)Following BD750 treatment, LPS-induced maturation of DC, allogeneic T cell proliferation, Th1 and Th17 cell functional differentiation, the STAT5 and AKT activation were determined.?The effect of tolDC loaded with antigen peptide on the development and severity of EAE and their splenic Th1 and Th17 cell responses were determined.?In comparison with LPS-induced mature DC (mDC), BD750 treatment induced tolDC with lower expression levels of costimulatory molecules and pro-inflammatory cytokines and lower levels of STAT5 phosphorylation.?TolDC inhibited allogeneic T cell proliferation and reduced Th1 and Th17 responses.Adoptive transfer of tolDC loaded with MOG35-55 inhibited the development and severity of EAE in mice, accompanied by reduced numbers of inflammatory infiltrates and decreased levels of demyelination in the spinal cord tissues of mice.?In addition, treatment with tolDC loaded with antigen peptide also significantly reduced the frequency of splenic Th1 and Th17 cells in EAE mice.?The effects of tolDC were similar to that of the JAK/STAT inhibitor, CP690550-treated DC.

BD750 inhibits human T cell proliferation stimulated either by anti-CD3/anti-CD28 mAbs or by alloantigen in a dose-dependent manner with IC50 values of 1.1 ± 0.2 μM and 1.3 ± 0.2 μM respectively.BD750 also inhibits ConA, PMA/ionomycine or alloantigen-induced mouse T cell proliferation and PHA or PMA/ionomycine-induced human T cell proliferation.BD750 (5 or 20 μM) inhibits the LPS-induced JAK-STAT5 signaling in DC.Western Blot Analysis Cell Line:Purified immature DCs.Concentration:1, 5 or 20 μM.Incubation Time:12 h.Result:Had fewer small dendrites and smaller clusters than typical mDCs (5 or 20 μM).At a higher dose significantly reduced the levels of LPS-stimulated IL-6, IL-12, TNF-α, IL-1β and IL-23 production by DCs.

BD750 can induce tolerogenic dendritic cells (tolDC) and their function in experimental autoimmune encephalitis (EAE) in mice. Animal Model:Female C57BL/6 mice (10 wks old, 19-21 g).Dosage:20 μM.Administration:IV, treated DC on d 7, 11 and 15 post the first PTX injection (dpi 7, 11 and 15).Result:Significantly reduced the frequency of Th1 and Th17 cells and increased the percentage of Tregs compared with mice receiving PBS.

——

Angiogenesis

JAK

JAK3|STAT5

——

——

892686-59-8

271.34

C14H13N3OS?

>98% (HPLC)

In Vitro:?DMSO : 125 mg/mL (460.68 mM)

O=c1c2CCCCc2[nH]n1-c1nc2ccccc2s1

——

(-20℃)

With Ice Pack

≥ 2 years